Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The systemic vasculitides are an uncommon group of autoimmune diseases capable of causing multi organ failure and death. Current immunosuppressive strategies have substantially improved the outcome, but the natural history of treated disease is unstable, typically characterised by frequent relapses, drug toxicity and an increasing burden of damage. Early diagnosis, accurate staging and regular evaluation of disease status are important in the management of the vasculitides. Clinical evaluation tools have been developed and provide a comprehensive assessment of patients. Serological markers, especially anti-neutrophil cytoplasm antibody (ANCA), pathology and imaging investigations are a useful addition, but are more valuable in diagnosis rather than monitoring of disease activity. Advances in magnetic resonance imaging in large vessel vasculitis have improved our ability to characterise disease and may lead to earlier diagnosis and better control in future. Development of new biomarkers is required in vasculitis, and this is likely to advance our understanding as well as the management of these complex conditions.

Original publication

DOI

10.1016/j.autrev.2008.07.001

Type

Journal article

Journal

Autoimmun rev

Publication Date

12/2008

Volume

8

Pages

170 - 175

Keywords

Antibodies, Antineutrophil Cytoplasmic, Humans, Quality of Life, Vasculitis